TGH Annual Report 2019

Greetings from the editorial office of Translational Gastroenterology and Hepatology(TGH).

We are pleased to present TGH's Annual Report for the year of 2019 here. In summary, TGH has published 84 articles with original articles and review articles accounting for 56% of the publication. The total citation of TGH has increased from 216 (2018) to 415 (2019). The average monthly pageviews of TGH in 2019 is 9099, compared to 5271 in 2018.

Read More>>

Application of the CARE Guideline as reporting standard in Translational Gastroenterology and Hepatology

Translational Gastroenterology and Hepatology welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.

For completeness and transparency for published case reports, Translational Gastroenterology and Hepatology will apply the CARE guidelines (1) as reporting standards for case reports starting from October 14, 2019.

Read More>>

Focused Issue on Liver injury by herbal products

This focused issue on “Liver injury by herbal products” is edited by Dr. Rolf Teschke from Teaching Hospital of the Goethe University of Frankfurt/Main, Germany.

Read More>>

Focused Issue on Gastrointestinal Cancer

This focused issue on “Gastrointestinal Cancer” is edited by Dr. Jaffer A Ajani, from Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Read More>>

Focused Issue: Translational study on Hepatocellular Carcinoma

There have been remarkable strides in the management of hepatocellular carcinoma, thanks to the collaboration between researchers and clinicians. It is high time for us to review the progress that we have made, and to look into the future. In the first half of this special issue of Translational Gastroenterology and Hepatology, we aim to highlight the changes in management of advanced hepatocellular carcinoma and how we have stretched the limits in difficult cases. In the latter half, we will look into the laparoscopic era of liver resection, and explore how we can train the younger generation and standardize the techniques. We hope that this issue can give a comprehensive update on the topic, and shed some light on potential developments to researchers and clinicians alike.

Read More>>

Focused Issue on Advanced Endoscopic Imaging of the GI Tract

This focused issue on “Advanced Endoscopic Imaging of the GI Tract” is edited by Dr. Krish Ragunath, from NIHR Nottingham Digestive Diseases Biomedical Research Centre, Queens Medical Centre, Nottingham University Hospital, Nottingham, UK; and Dr. Philip Wai Yan Chiu, from Department of Surgery, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.

Read More>>

Focused Issue on GI Malignancies and Immunotherapy

This focused issue on “GI malignancies and Immunotherapy” is edited by Dr. Khaldoun Almhanna, from Department of Hematology/Oncology, Lifespan Cancer Institute, Providence, RI, USA.

Read More>>

Focused Issue on Liver Transplantation in NASH and ALD

This focused issue on “Liver Transplantation in NASH and ALD” is edited by Dr. Sanjaya Satapathy, from Liver Transplantation at the Northshore University Hospital/Northwell Health, Manhasset, NY, USA; David E. Bernstein, from Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA; and Dr. Nitzan C. Roth, from Sandra Atlas Bass Center for Liver Diseases Department of Medicine Northwell Health, Manhasset, NY, USA.

Read More>>

Focused Issue on Recent Advances in Rare Liver Diseases

This focused issue on “Recent Advances in Rare Liver Diseases” is edited by Dr. Luca Fabris, from Department of Molecular Medicine (DMM), University of Padua, Padua, Italy; and Dr. Mario Strazzabosco, from Department of Internal Medicine, Yale University, New Haven, CT, USA.

Read More>>

Focused Issue on Non-alcohol Fatty Liver Disease and Alcohol Liver Disease

This focused issue on “Non-alcohol Fatty Liver Disease and Alcohol Liver Disease” is edited by Dr. Ashwani K. Singal, Division of Gastroenterology and Hepatology, University of South Dakota, Sioux Falls, SD, USA.

Read More>>

Focused Issue: Gastrointestinal Carcinoma and Sarcoma Surgery

A number of advances in both earlier diagnostic imaging and better treatment options for patients with intra-abdominal malignancies have occurred. Frequently such newer therapies rely on the integration of established surgical and radiation approaches potentially with newer chemotherapies and immunomodulators. Unfortunately, with further study some newer therapies have proven less beneficial than initially suggested. Keeping up with the data supporting newer alternatives, and determining which therapies to provide patients can be a challenge. Nonetheless, integrating newer study data into beneficial therapeutic algorithms and understanding the molecular basis and rationale for new therapies remains a critically important role for treating physicians. To help provide busy clinicians and trainees with a current update for the management of intra-abdominal malignancies, this special issue of Translational Gastroenterology and Hepatology provides succinct reviews relevant to both diagnosis and treatment for patients with abdominal sarcoma or adenocarcinoma.

Read More>>

Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry

Figure 5 Leiomyoma (×200). (A) HE staining; (B) desmin IHC; (C) KIT IHC; (D) S100P IHC. IHC, immunohistochemistry.

Read More>>

Utility and performance characteristics of a novel submucosal injection agent (EleviewTM) for endoscopic mucosal resection and endoscopic submucosal dissection

Figure 1 Performance of cecal EMR using EleviewTM. (A) Cecal polyp spanning across a fold, without any suspicious or high-risk features; (B) injection of EleviewTM for submucosal lifting; (C) mucosal resection of the polyp using snare; (D) post-EMR defect, which was then closed with hemoclips. EMR, endoscopic mucosal resection.

Read More>>

Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines

Figure 3 Genotypes of GIST. Carney-Stratakis syndrome is a dyad of paraganglioma and gastric GIST with autosomal dominance. Carney triad is characterized by three neoplasms of gastric GIST, pulmonary chondroma, and extra-adrenal paraganglioma. A part of the algorithm is similar to (25). #, indicates syndromic GIST. GIST, gastrointestinal stromal tumor; SDH, succinate dehydrogenase; NF1, neurofibromatosis type 1.

Read More>>

Modifications in the International Study Group for Pancreatic Surgery (ISGPS) definition of postoperative pancreatic fistula

Figure 1. Change in POPF diagnosis. POPF, postoperative pancreatic fistula; ISGPF, the International Study Group of Pancreatic Fistula.

Read More>>

Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review

Table 1. World reported series of liver transplantation after Y90-RE

Read More>>

Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Table 2. Influence of immunosuppressive drugs on (de novo) tumour development.

Read More>>

Function-preserving surgery for gastric cancer: current status and future perspectives

Figure 1. The distal stomach was divided while remaining a 4–5 cm pyloric cuff. The proximal remnant stomach was then revised just proximal to demarcation line between the right and left gastroepiploic artery.

Read More>>

The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution

Table 2. Recommendations on the prognostic role of alpha-fetoprotein as reported in the most recent international guidelines on hepatocellular cancer management

Read More>>

Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Figure 1. A proposed algorithm for selection of patients for liver transplantation based on the BCLC tumor stage and on risk factors indicating unfavourable tumor biology. BCLC, Barcelona clinic liver cancer; AFP, alpha-fetoprotein; PET, positron emission tomography.

Read More>>